CompletedPHASE2, PHASE3NCT01600703
Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans
Studying Disorder of lipid metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Health Network, Toronto
- Principal Investigator
- Gary Lewis, MD, mdUHN
- Intervention
- Sitagliptin(drug)
- Enrollment
- 21 target
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2012 – 2013
Study locations (1)
- Toronto General Hospital, Toronto, Ontario, Canada
Collaborators
Merck Frosst Canada Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01600703 on ClinicalTrials.govOther trials for Disorder of lipid metabolism
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06695325Convenient Home Access for Routine Monitoring in Diabetes (Charm-D Study)Tameside General Hospital
- RECRUITINGPHASE1NCT06947304Evaluation of Miricorilant on Liver Fat in Patients With MASLDCorcept Therapeutics
- ACTIVE NOT RECRUITINGPHASE2NCT07028749Study of MAR001 in Adults With Elevated Triglycerides and Remnant CholesterolMarea Therapeutics
- ENROLLING BY INVITATIONPHASE4NCT06845345Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)Carmen Dietvorst
- RECRUITINGPHASE3NCT06643130Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and DyslipidemiaJW Pharmaceutical
- ENROLLING BY INVITATIONNANCT06822621Functional Cereal Products and Contribution to the Regulation of Metabolism and Obesity-induced Chronic Low-grade Inflammation.Harokopio University
- ACTIVE NOT RECRUITINGPHASE3NCT06492291Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef ExtensionMerck Sharp & Dohme LLC
- RECRUITINGNCT06206759Vitamin C Administration and Triglycerides Level in Critical Care PatientsMeir Medical Center